Surface Oncology

CAMBRIDGE, MA

Surface is developing unique antibodies that modulate a series of orthogonal pathways to the immune checkpoint pathways, which will be used therapeutically in conjunction with existing checkpoint inhibitors for the treatment of oncology patients. These new classes of cancer immunotherapeutics have the specific goal of augmenting the significant clinical effect the current checkpoint inhibitors have shown, expanding the effectiveness and utility of this approach to a broad spectrum of patients. Surface leverages a world-class SAB to direct efforts in this novel biology space, and an efficient infrastructure to develop these therapeutic agents clinically.

Other investors include: Atlas Ventures, Amgen Ventures, Fidelity Bioventures, NEA, and NIBR.